Presentation is loading. Please wait.

Presentation is loading. Please wait.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63.

Published byIrma Richards Modified over 9 years ago

Similar presentations

Presentation on theme: "Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63."— Presentation transcript:

1 Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

2 Characteristics of selected major statin trials Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

3 Updated meta-analysis of major statin trials that assessed the effect of statins on fatal and non-fatal stroke Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

4 Updated meta-analysis of major statin trials that assessed the effect of statins on fatal stroke Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

5 Updated meta-analysis of major statin trials that assessed the effect of statins on haemorrhagic stroke Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

6 Association between reduction in LDL cholesterol concentration with stroke incidence among the major statins trials Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

7 Meta-analysis of statin trials that assessed the effect of intensive lipid-lowering therapy versus standard statin therapy on incidence of fatal and non-fatal stroke and on major cardiovascular events Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63

Download ppt "Amarenco P, Labreuche J. Lancet Neurol 2009;8:453-63."

Similar presentations

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.
SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9:269-279. LaRosa JC et al. N Engl J Med. 2005;352:1425-1435.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Lancet 2005 366: 1267-1134 doi:10.1016/S0140-6736(08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:2998-3007 ALLHAT- LLT.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Slide Source: www.lipidsonline.org Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.

Slide Source: Primary and Other Outcomes: DREAM Rosiglitazone group (n=2635) Placebo group (n=2634)HR (95% CI)p Composite primary.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Lipid Management in Stroke : Statin and Other Lipid Modifying Agents Professor Pierre Amarenco INSERM U-698 and Paris-Diderot University Department of.

Lipid Management in Stroke : Statin and Other Lipid Modifying Agents Professor Pierre Amarenco INSERM U-698 and Paris-Diderot University Department of.
The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,

The concept of Diabetes & CV risk: A lifetime risk challenge The Clinical Significance of LDL-Cholesterol: No Longer a Hypothesis? John J.P. Kastelein,
Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Lancet 373:1765-72, 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Similar presentations

Ads by Google